GLP-1 Weight Loss Drugs Expected to Reach Less Than 10% of Eligible Patients, Experts Say

In a significant move to address the growing global obesity crisis, the World Health Organization (WHO) has issued its first-ever official guidance on the use of GLP-1 medications for obesity treatment. The guidelines, released on December 1, represent a major shift in how obesity is approached on a global scale.

GLP-1 drugs, which mimic the natural hormone glucagon-like peptide-1, have gained prominence for their effectiveness in both type 2 diabetes management and medical weight loss. These medications were added to WHO’s Essential Medicines List for diabetes treatment in September 2025, but the new guidelines specifically address their application for obesity.

Obesity currently affects more than one billion people worldwide and is associated with approximately 3.7 million deaths annually. Experts project these numbers will double by 2030, highlighting the urgent need for effective interventions.

The WHO’s recommendations come with two key conditions. First, “GLP-1 therapies may be used by adults, but excluding pregnant women, for the long-term treatment of obesity.” While acknowledging the drugs’ efficacy, the WHO notes that this recommendation is conditional due to limited long-term safety data, current high costs, and concerns about healthcare system preparedness and equity issues.

The second condition emphasizes that “intensive behavioral interventions” should accompany medication. These include healthy diets, regular physical activity, and professional healthcare support as part of a comprehensive treatment approach.

“Our new guidance recognizes that obesity is a chronic disease that can be treated with comprehensive and lifelong care,” stated Dr. Tedros Adhanom Ghebreyesus, WHO Director-General. “While medication alone won’t solve this global health crisis, GLP-1 therapies can help millions overcome obesity and reduce its associated harms.”

The economic impact of obesity is equally concerning. Global costs related to obesity management and complications are projected to reach $3 trillion annually by 2030. The WHO guidelines aim to reduce these “skyrocketing” healthcare expenditures while addressing the condition itself.

A significant focus of the WHO recommendations is ensuring equitable access to these treatments. “Without deliberate policies, access to these therapies could exacerbate existing health disparities,” the organization warned. Despite rapid expansion in GLP-1 production, by 2030, these therapies are predicted to reach less than 10% of potential beneficiaries worldwide.

To address this gap, the WHO is calling for strategies to expand access, including “pooled procurement, tiered pricing and voluntary licensing among others.” This reflects growing concerns that these medications, which can cost hundreds of dollars monthly in many markets, may primarily benefit wealthy populations while remaining inaccessible to those in lower-income regions.

The guidelines also acknowledge that obesity is a “complex, chronic disease” that drives other serious health conditions, including cardiovascular disease, type 2 diabetes, and certain cancers. While GLP-1 medications represent what the WHO calls “the first efficacious treatment option for adults,” the organization stresses the need for comprehensive approaches.

These approaches include creating healthier environments to prevent obesity, implementing screening and early interventions for high-risk individuals, and ensuring lifelong healthcare access for those affected.

The announcement represents a significant evolution in global health policy regarding obesity treatment. By officially recognizing GLP-1 medications as legitimate options for obesity management while emphasizing their place within broader treatment frameworks, the WHO is providing countries with a roadmap for addressing one of the most pressing public health challenges of our time.